Suraksha Diagnostic LtdQ1 FY27
Suraksha Diagnostic Ltd Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹317P/E: 44.4Market Cap: ₹1.6K CrSector: Healthcare Services
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- →The company expects steady revenue growth, targeting around 15% annually, reflecting a conservative approach as they mature their operations.
- →Test volume growth has been robust historically (~20% YoY), though recent quarters showed some moderation (~10-11%). Volume growth remains a key driver.
- →Expansion plans include adding approximately 20 new labs in FY '27, with about 50% of new centers in newer geographies beyond core regions like Kolkata and West Bengal.
- →Genomics business is seen as a significant growth pillar, with strong adoption and market education efforts underway; expected to contribute meaningfully over the next 3-4 years.
- →Mature centers showed ~12.5% revenue growth quarter-on-quarter, expected to sustain this momentum.
- →The company is on track to open 100 centers by FY '28, expanding its network and geographic footprint.
- →Overall, sales, volumes, and revenues are expected to increase driven by network expansion, new test offerings, and deeper market penetration.
Margin guidance
Category 3- →Revenue growth guidance is a conservative 15% in FY '27 but management aims for robust growth fueled by network expansion and new geographies.
- →EBITDA margins expected to increase; mature centers have achieved ~40.9% EBITDA margin, with overall target around 34% margin sustainable through FY '28 and beyond.
- →Genomic business, contributing margins around 15-20%, expected to witness strong continued growth and is a key growth pillar.
- →Test volume growth steady though moderate (~10-11% in Q1 FY '27), with potential to improve as genomic testing gains traction.
- →New centers currently breaking even within months, expected to improve overall profitability as they scale.
- →Company expanding aggressively toward 100 centers by FY '28, investing Rs. 70-80 crores/year.
- →PAT growth strong: 40% YoY increase in Q1 FY '27, with continued market education and genomic adoption aiding future profitability.
3 more insights locked — sign up free to unlock
Fundraise plans
- →The transcript does not explicitly mention any current or planned fundraising through debt or equity.
- →The company is focusing on expansion, with plans to open more centers and invest in genomics, with a Capex outlook around Rs. 70-80 crores for the year.
- →Discussions around investments primarily relate to operational Capex for new hubs, spokes, and genomics capacity.
- →The management highlights a conservative approach towards revenue guidance and a focus on organic growth.
- →They also mention exploring inorganic acquisition opportunities if good quality and price arise, but no explicit mention of related fundraising.
- →Overall, no direct information on new fundraising via debt or equity is provided in this call.
Order book
The transcript provided does not explicitly mention the current or expected order book or pending orders for Suraksha Diagnostic Limited. However, relevant growth and expansion insights include:
- The company is on track to open 100 centers by FY '28, indicating a strong expansion pipeline.
- Plans to add approximately 20 labs in FY '27, with about 50% in new geographies beyond Kolkata and West Bengal.
- Genomic testing capacity has been significantly invested in (Rs. 22 crores over 3 years) with expectations of strong growth.
- No specific mention of order book or pending orders was made during the Q&A.
Therefore, while clear order book numbers are not stated, the company signals ongoing and planned capacity expansion, especially in labs and genomics, supporting a robust expected business pipeline.
Capex plans
Yes- →Genomic Capacity Investment: Rs. 22 crores invested over 3 years in genomic labs (Page 15).
- →Future Genomics Capex: No substantial incremental CapEx expected in genomics for the next 2-3 years; existing CapEx is sufficient to leverage growth (Page 10).
- →FY '27 Capex Outlook: Rs. 70-80 crores planned for the financial year for network expansion (Page 6).
- →Center Expansion: Plan to open 6 spokes and 3 hubs in the current year, beyond centers already opened (Page 10).
- →Strategic Exploration: Actively exploring inorganic acquisition opportunities if quality and price are favorable (Page 15).
- →Target to open 100 centers by FY '28 on track with planned Capex (Page 6).
How does Suraksha Diagnostic Ltd rank vs peers in Healthcare Services?
Pro feature1Suraksha Diagnostic Ltd
Rev 3Mar 3
See full Healthcare Services sector rankings
How does Suraksha Diagnostic Ltd rank in Healthcare Services?
Compare Suraksha Diagnostic Ltd against every Healthcare Services company (Q1 FY27) on revenue, margins and earnings-call signals.